Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection (Combina)
|ClinicalTrials.gov Identifier: NCT00830323|
Recruitment Status : Terminated
First Posted : January 27, 2009
Last Update Posted : September 30, 2010
Neuraminidase inhibitors (NAI) are effective anti-influenza antiviral treatment. During their use in experimentally infected patients, it has been shown that the viral load detected in the nasal fluid is decreasing significantly faster than in non treated patients. During clinical practice, the emergence of NAI-resistant strains has been observed. These strains remain rare, but their emergence seemed to be related to the mis-use of the NAI products (insufficient duration or dosage). This observation as well as the detection of NAI-resistant viruses in the community raises concerns about putative emergence of resistant clones in the specific context of a pandemic, when the use of NAI will be very large in the aim of reducing transmission, and subsequently the impact of the emerging virus.
In this context, it is important to determine the putative interest of alternative strategies.
Although zanamivir and oseltamivir are both issued from the same class , this combination may lead to a more rapid viral clearance in the infected cases, and to a reduction in the emergence of resistant sub-clones, and alternatively, might lead to a competitive inhibition. The evaluation of these combinations needs to be conducted in vivo.
Among available anti influenza antivirals, M2 blockers have been previously used. Although their efficacy against A H5N1 remains to be ascertained, their use in combination with NAI should also be evaluated in the context of a preparation for a possible pandemic and determination of the stockpile.
Therefore, the evaluation of combination therapies in the treatment of a virologically suspected influenza will be investigated in primary care during the winter season 2008-2009.
|Condition or disease||Intervention/treatment||Phase|
|Influenza A Infection||Drug: oseltamivir + zanamivir Drug: oseltamivir+ amantadine Drug: oseltamivir||Phase 2|
- Patient's follow up: 7 days with 10 visits V1, V2, V3, V4, V5 every 12 hours V6, V7, V8, V9, V10 every 24 hours
- V1: conducted by the GP rapid test diagnostic for influenza A, urine pregnancy test for women, inclusion /randomisation, nasal sample, initiation of treatment.
- V2 to V9: conducted by a nurse at the patient's home; nasal sample, symptoms scoring, safety assessment (side effects)
- V 10: conducted by GP; medical evaluation (follow up evaluation)
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||August 2009|
|Estimated Study Completion Date :||August 2009|
Drug: oseltamivir + zanamivir
oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
|Experimental: Arm 2||
Drug: oseltamivir+ amantadine
oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
|Active Comparator: Arm 3||
oseltamivir (75mg bd for 5 days, oral)
- describe the antiviral efficacy in the 3 arms in the treatment of seasonal influenza infection as assessed by negative viral detection in nose swabs at the fifth swab [H48±3] [ Time Frame: 48 hours ]
- Describe the antiviral efficacy in 3 arms in the treatment of seasonal influenza infection as assessed by negativity of RT-PCR for viral RNA in nose and throat swabs at the 5th swab [H48±3] and at the 7th swab [H84±3]. [ Time Frame: 84 hours ]
- Describe the antiviral efficacy in combination therapy arms (1,2) and in monotherapy arm (3) in the treatment of seasonal influenza infection as assessed by time to sustained negativity of RT-PCR for viral RNA or viral culture in any sample. [ Time Frame: 168 hours ]
- Assess viral replication dynamics (duration and level of viral replication) in the respiratory tract in the combination and standard-dose cohorts. [ Time Frame: 168 hours ]
- Assess the frequency, genetic basis, and duration of antiviral resistance to each arm during and after therapy [ Time Frame: 168 hours ]
- Describe the time to alleviation of illness in the 3 arms defined as the time from the beginning of the study treatment to the time that 7 typical key symptoms of natural influenza had reduced to absent or mi [ Time Frame: 168 hours ]
- Describe the tolerability of combination and in standard-dose arms as assessed by clinical adverse events that are possibly or probably related to each single agent (Incidence and duration) [ Time Frame: 168 hours ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00830323
|Hospices civils de Lyon|
|Principal Investigator:||BRUNO LINA, MD,PhD||Hospices Civils de Lyon|